RecruitingNCT07140770

Sleep and Physical Activity in Patient and Caregiver Dyads Following Allogeneic Hematopoietic Cell Transplantation


Sponsor

M.D. Anderson Cancer Center

Enrollment

66 participants

Start Date

Sep 2, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

To understand the changes in health-related quality of life of patients and caregivers after allogeneic hematopoietic cell transplantation.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Eligibility Criteria
  • Participants and caregivers ages 18 years and older.
  • Participants diagnosed with a hematologic malignancy with a scheduled allogeneic HCT.
  • Caregivers identified by participant as the primary caregiver.
  • Participants and caregivers able to read, speak, and consent in English.
  • Participants and caregivers able to understand and be willing to sign a written informed consent document.
  • Participants and caregivers must have internet access via smart phone or tablet with the capacity to 1) download the Fitbit app and 2) complete study assessments with study

Exclusion Criteria4

  • Participant or caregiver unable to provide consent, such as cognitively impaired individuals
  • Participant or caregiver with a diagnosis of sleep apnea.
  • Primary caregiver is a paid professional, such as a live-in Registered Nurse.
  • Participant has multiple caregivers and is unable to identify one primary caregiver.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEFitbit

You will wear the tracker on your wrist like a watch and it will continuously (non-stop) monitor your activity, sleep, and heart rate. Functional testing will be completed with a research team member and will consist of 2 tests: testing your grip strength by having you squeeze a measuring device 3 times with your dominant hand and measuring how many minutes it takes for you to walk 15 feet.

OTHERQuestionnaire

Complete questionnaires at 3 timepoints, at the time of enrollment on the day of allogeneic hematopoietic cell transplantation, 8 days after allogeneic hematopoietic cell transplantation, and 7 days after hospital discharge.


Locations(1)

MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07140770


Related Trials